ArticleFrontiers in immunology2023

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Patrick Greve et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.